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Background and purpose: Myelin oligodendrocyte glycoprotein- antibody– associated 
disease (MOGAD) is an inflammatory autoimmune condition of the central nervous sys-
tem. However, data on pain and depression have remained scarce. The aim of this study 
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INTRODUC TION
Myelin oligodendrocyte glycoprotein- antibody (MOG- ab)- associated 
disease (MOGAD) is an inflammatory autoimmune condition of 
the central nervous system [1,2]. MOG- abs bind conformationally 
intact myelin oligodendrocyte glycoprotein (MOG) and induce an 
inflammatory demyelination [3]. MOGAD patients may develop 
any combination of monophasic or relapsing optic neuritis (ON), 
transverse myelitis, acute disseminated encephalomyelitis, brain-
stem symptoms, and less frequently, cortical involvement with 
seizures [1,4– 6]. The clinical phenotype in adults is partly similar 
to aquaporin- 4- antibody (AQP4- ab)– positive neuromyelitis spec-
trum disorder (NMOSD) [4]. However, based on a distinct immu-
nopathogenesis, MOGAD is now considered a disease entity on 
its own [7– 9].
In NMOSD, severe pain is one of the most frequent and dis-
abling symptoms. Pain has a prevalence of over 80% and se-
verely reduces the quality of life (QoL) [10– 12]. Pain syndromes 
embrace neuropathic pain, nociceptive pain, and mixed pain, and 
can emerge in acute relapse or become chronic within the disease 
course [10– 12]. Characteristic painful tonic spasms (PTS) occur in 
approximately 20% of patients with AQP4- ab– related NMOSD 
[13].
In MOGAD, data on pain are scarce, and clinical case reports and 
series often ignore pain as a severe symptom. However, ON- related 
headache or periorbital pain, neuropathic pain, including radiculopathy- 
like pain, and musculoskeletal pain have all been described anecdotally 
and can severely affect the patient’s well- being [4,12,14– 17].
In the current study we performed a systematic analysis of neu-
ropathic and nociceptive pain syndromes, as well as depression, and 
their impact on QoL and activities of daily living (ADL) in adults with 
MOGAD in Germany.
METHODS AND MATERIAL S
We performed an exploratory cross- sectional study in the years 
2017 to 2019. MOG- ab– positive patients were identified through 
the registry of the German Neuromyelitis Optica Study Group 
(NEMOS; www.nemos - net.de) and through local electronic da-
tabases. A semistructured questionnaire, which was given to the 
patients by the local staff of the 11 participating tertiary referral 
centers, was sent back to the Bochum or Berlin centers in a pseu-
donymized fashion.
Inclusion criteria were: (i) age over 18 years, (ii) diagno-
sis of MOGAD [2] with positive cell- based assay detecting 
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was to assess features of chronic pain and depression as well as their impact on health- 
related quality of life (hr- QoL) in MOGAD.
Methods: Patients with MOGAD were identified in the Neuromyelitis Optica Study 
Group registry. Data were acquired by a questionnaire, including clinical, demographic, 
pain (PainDetect, Brief Pain Inventory– Short Form, McGill Pain Questionnaire– Short 
Form), depression (Beck Depression Inventory- II), and hr- QoL (Short Form- 36 Health 
Survey) items.
Results: Twenty- two of 43 patients suffered from MOGAD- related pain (11 nociceptive, 
eight definite neuropathic, three possible neuropathic) and 18 from depression. Patients 
with neuropathic pain had the highest pain intensity and most profound activities of daily 
living (ADL) impairment. Fifteen patients reported spasticity- associated pain, includ-
ing four with short- lasting painful tonic spasms. Later disease onset, profound physical 
impairment, and depression were associated with chronic pain. Physical QoL was more 
affected in pain sufferers (p < 0.001) than in pain- free patients, being most severely 
reduced by neuropathic pain (p = 0.016). Pain severity, visual impairment, and gait im-
pairment independently predicted lower physical QoL. Depression was the only factor 
reducing mental QoL. Twelve patients still suffering from moderate pain (pain severity 
4.6 ± 2.3) received pain medication. Only four out of 10 patients with moderate to severe 
depression took antidepressants.
Conclusions: Being highly prevalent, pain and depression strongly affect QoL and ADL 
in MOGAD. Both conditions remain insufficiently controlled in real- life clinical practice.
K E Y W O R D S
depression, MOG- antibody– associated disease, pain, quality of life, spasticity
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MOG- immunoglobulin G (IgG). Exclusion criteria comprised (i) other 
diseases with relevant pain syndromes and (ii) severe cognitive 
deficits.
Clinical data and assessment
The questionnaire comprised questions on demographics, dis-
ease course, previous relapses (history of ON and myelitis), 
current therapy, spasticity, as well as pain, depression, and health- 
related quality of life (hr- QoL) assessment scores (PainDetect 
Questionnaire [PDQ], Short Form of the Brief Pain Inventory 
[SF- BPI], McGill Pain Questionnaire Short Form [MPQ- SF], Beck 
Depression Inventory II [BDI- II], and Short Form 36 Health Survey 
[SF- 36]).
Spasticity was assessed by asking if the patient experienced at-
tacks or short episodes (<1 min) of intensive pain, accompanied by 
an increased tone (increased muscular tension) and cramps in the 
arms/legs.
The questions of the SF- BPI consist of two categories: (i) pain 
severity (present, highest, least, and average pain intensity) based on 
a numeric rating scale from 0 (no pain) to 10 (worst pain imaginable) 
within the last week. The pain severity index (PSI) represents the 
average score of the four pain intensity scores; (ii) seven domains of 
pain- related interference with daily life, rated from 0 (no interfer-
ence) to 10 (complete interference): general activity, mood, walking 
ability, working ability, relations with other people, sleep, and enjoy-
ment of life.
The PDQ was administered to ask about pain localization and 
to discriminate between neuropathic (PDQ score, 19– 38) and 
nociceptive pain (PDQ score, 0– 12). PDQ score from 13 to 18 is 
considered to be possibly neuropathic [18]. We performed com-
parative analysis between patients with definitive neuropathic 
and nociceptive pain.
The MPQ- SF consists of 15 words describing sensory (n = 11) 
and affective (n = 4) components of pain. Patients rate the intensity 
of the respective pain quality as 0 = none, 1 = mild, 2 = moderate, or 
3 = severe [19].
The BDI- II ranges from 0 (best) to 63 (worst) (<9: no depressive 
affect; 9– 13: minimal mood disturbance; 14– 20: mild depression, 
21– 28: moderate depression; ≥29: severe depression). Clinically rel-
evant depression was defined by a BDI score ≥14 [20].
SF- 36 measures hr- QoL. It consists of 36 items in eight subscales 
with components of mental and physical health. A physical compo-
nent summary (PCS) and a mental component summary (MCS) were 
calculated using norm- based attaining values from 0 (worst) to 100 
(best) [21].
Patient- reported gait function (scored from 0 [best] to 3 
[worst]; 0: no restriction; 1: >500 m without rest, 2: <500 m with-
out rest, 3: inability to walk) and visual function (scored from 0 
[best] to 4 [worst]; 0: no restriction; 1: restricted when reading, 
writing, or working on a PC only; 2: restricted during simple ac-
tivities of daily life at home; 3: very bad vision, no orientation in a 
foreign environment; 4: shadow vision, blindness) were assessed 
corresponding to the questionnaires’ relapse history (ON: visual 
function; myelitis: gait function).
In addition to the patient- reported questionnaire, the Expanded 
Disability Status Scale (EDSS) was evaluated if available at the re-
spective study center. The EDSS was assessed within 12 months 
relative to the questionnaire. Therefore, the analysis was focused 
on self- reported gait and visual function at the time of assessment.
Testing for serum MOG- abs was performed per local protocols 
using established cell- based assays [2,8].
Statistics
Statistical analysis was performed using R (version 3.4.0; The R 
Foundation for Statistical Computing) [22]. To investigate group 
differences, we used the Fisher exact test for categorical variables 
(attack history, BDI- II score categories, sex, group comparisons of 
patients with intermittent vs. permanent pain), Mann- Whitney- 
Wilcoxon rank sum test for not normally distributed continuous vari-
ables (age, disease duration, self- reported gait and visual function, 
McGill Pain Questionnaire [MPQ] scores, measures of pain intensity, 
number of attacks, SF- 36 scores, SF- BPI scores).
To check for correlations between measures of pain intensity 
and depression scores and for correlations between measures of 
pain intensity, depression scores, self- reported physical impairment, 
and PCS and MCS, respectively, we performed a Spearman correla-
tion test. We performed an additional correlation analysis of PCS 
and MCS with the EDSS as an objective impairment score. A robust 
regression model [23] was used to determine predictors of hr- QoL 
with SF- 36 PCS and MCS score.
For all models and corresponding statistical tests, statistical sig-
nificance was set at p < 0.05. This study was exploratory, without an 
a priori sample size calculation and adjustments for multiple testing.
RESULTS
Description of cohort
Forty- three adult patients with MOGAD were included in the analy-
sis. Table 1 provides the main demographic and clinical character-
istics of the study participants. Current immunotherapy comprised 
azathioprine (n = 5), glatiramer acetate (n = 1), intravenous or subcu-
taneous immunoglobulin (n = 3), methotrexate (n = 2), mitoxantrone 
(n = 1), mycophenolate mofetil (n = 1), prednisolone (n = 1), and rituxi-
mab (n = 19).
Prevalence of pain in MOGAD
Pain was a frequent symptom in our cohort. Overall, 22 of 43 (51%) pa-
tients suffered from chronic MOGAD- related pain. Eighteen patients 
1648  |    ASSEYER Et Al.
(42%) reported painful symptoms as part of their previous attacks. Of 
these, nine patients had transient pain only, and nine patients had per-
sistent pain. Attack- related pain comprised myelitis- associated pain 
(n = 6), ON- associated pain (n = 7), and nonspecific pain like headache 
(n = 4), neck pain (n = 1), and generalized body pain (n = 1).
Pain quality, intensity, and localization of relapse- 
independent pain
The following analysis of pain syndromes was performed in patients 
with relapse- independent MOGAD- related pain (n = 22). Pain was 
mainly described as cramping (n = 11), stabbing (n = 15), tender 
(n = 17), aching (n = 19) (sensory dimensions), and tiring/exhaust-
ing (n = 20) (affective dimension). Median present pain intensity was 
3/10 (minimum– maximum: 0– 9), median maximum and average pain 
intensity in the previous week were 6/10 (minimum– maximum: 1– 9) 
and 3.5/10 (minimum– maximum: 1– 9), respectively.
Of 22 patients with MOGAD- related pain, 12 suffered from per-
manent pain and nine from intermittent pain attacks. For one patient, 
no information was available. Six patients suffered from both perma-
nent pain and pain attacks. Patients with pain attacks had the most 
severe pain: median PSI 4.4 (minimum– maximum: 2.5– 9) in those 
with additional permanent pain and 4.3 (minimum– maximum: 1.5– 
6.5) in those without. Patients with persistent pain without attacks 
had the lowest median PSI: 2.1 (minimum– maximum: 1– 4). Pain was 
localized mostly in the legs (n = 14, n = 11 bilaterally), following by 
back pain (n = 12), arm pain (n = 8, n = 4 bilaterally), head/neck pain 
(n = 6), and anterior trunk pain (n = 3).
Pain- associated factors
Demographics were similar in patients with and without pain 
(Table 2). However, patients with MOGAD- related pain were older at 
disease onset (p = 0.039) and clinically more impaired than patients 
without pain (self- reported gait function: p = 0.005). Moreover, 
clinically relevant depression was more frequent in pain sufferers 
(p = 0.034).
Neuropathic and nociceptive pain
Eight of 22 patients with MOGAD- related pain fulfilled the PDQ 
criteria for definite neuropathic pain, three patients had a possible 
neuropathic pain component, and 11 patients had nociceptive pain.
As expected, patients with definite neuropathic pain had higher 
pain intensity scores than those with nociceptive pain (Table 3). They 
described their pain experience more often as shooting (p < 0.001), 
sharp (0.014), hot– burning (p = 0.018) (sensory dimensions), and 
fearful (p = 0.032) (affective dimension). Sensory and affective pain 
scores were also higher in patients with neuropathic pain. The groups 
did not differ with respect to age, sex, disease duration, number of 
relapses, annualized relapse rate, number with ON, and number with 
myelitis. However, patients with definite neuropathic pain had more 
severe gait restriction (p = 0.032) than patients with nociceptive pain.
Spasticity- associated pain
Fifteen patients reported spasticity- associated pain (SAP). SAP was 
located in one (n = 6) or both legs (n = 9), or in both arms and in the 
back for one patient, respectively. Four patients (18.2%) presented 
short- lasting PTS. Patients with SAP had a trend toward higher num-
bers of previous relapses (p = 0.051) and surprisingly shorter disease 
duration (p = 0.048) than patients without SAP (Table 4). Patients 
with and without SAP did not differ with respect to demographics 
and depression prevalence.
Depression is more prevalent in pain sufferers
Eighteen patients (41.9%) had signs of clinically relevant depression 
that was at least moderate (BDI ≥ 21) in 10 (23.3%) cases. Clinically 
relevant depression was more prevalent in pain sufferers than in 
patients without disease- related pain (59.1% vs. 25%, p = 0.034; 
Table 2). Demographics, disease duration, and relapse activity did 
not differ between patients with and without clinically relevant de-
pression (Table 5). The depression score did not differ between pa-
tients with nociceptive versus neuropathic pain (Table 3) or between 
TA B L E  1  Demographic and clinical characteristics of patients 
included in this study
MOG- ab– positive 
patients, n = 43
Sex, female/male (female %) 29/14 (67.4%)
Age, years, mean±SD 39.2 ± 14.7
Age at disease onset, years, mean±SD 33.5 ± 14.0
Disease duration, years, median (min- max) 3 (0– 43.7)
Total number of previous attacks, median 
(min- max)a
3 (1– 16)
Patients with a history of myelitis, n (%)b 34 (81%)
Patients with a history of ON, n (%)a 31 (77.5%)
Total number of ON attacks, median 
(min- max)c
1 (0– 10)
Total number of myelitis attacks, median 
(min- max)d
1 (0– 11)
EDSS, median (min- max)e 2.5 (0– 8)
Patients on current immunosuppressive 
treatment, n (%)a
33 (82.5%)
Note: Relapse history included only previous attacks of ON and myelitis 
but no other possible manifestations. Percentages refer to the number 
of available data. Data available for an = 40, bn = 42, cn = 38, dn = 37, 
en = 33.
Abbreviations: EDSS, Expanded Disability Status Scale; min- max, 
minimum– maximum; MOG- ab, myelin oligodendrocyte glycoprotein- 
antibody; n, number; ON, optic neuritis; SD, standard deviation.
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patients with permanent and intermittent pain (odds ratio: 1.1; 95% 
confidence interval: 0.1– 8.8; p = 1.0). However, depression severity 
correlated with a visual (ρ = 0.401, p = 0.009) and gait (ρ = 0.333, 
p = 0.041) impairment as well as pain intensity (PSI: ρ = 0.392, 
p = 0.010).
Pain and depression strongly affect hr- QoL and ADL 
in MOGAD
Both physical and mental components of the QoL were altered 
in patients with MOGAD, with a median MCS of 43.2 (minimum– 
maximum: 21.1– 63.9) and a PCS of 42.4 (minimum– maximum: 
9.4– 65.8) compared to the general population [21]. The physical 
component score was lower in patients with pain than in pain- free 
patients (Table 2). Moreover, this score was lower in patients with 
neuropathic pain than in patients with nociceptive pain (Table 3). 
Also, patients with depression had significantly lower MCS and PCS 
scores than patients without depression (Table 5).
Pain strongly affected all aspects of ADL: general activity, 5.5/10 
(minimum– maximum: 1.5– 10); walking ability, 5.5/10 (minimum– 
maximum: 0– 10); mood, 5/10 (minimum– maximum: 1– 10); working 
ability, 5/10 (minimum– maximum: 1– 10); sleep 4/10 (minimum– 
maximum: 0– 9); enjoyment of life, 3.5/10 (minimum– maximum: 0– 
8); and relations with other people 3/10 (minimum– maximum: 0– 10).
Pain severity (ρ = −0.798, p < 0.001), gait (ρ = −0.690, p < 0.001), 
and visual impairment (ρ = −0.370, p = 0.024), as well as depression 
score (ρ = −0.361, p = 0.022) correlated with PCS. In a regres-
sion model including these four factors, pain severity (B = −5.455, 
SE = 0.810, p < 0.001), visual function (B = −8.163, SE = 1.742, 
p < 0.001), and gait function (B = −5.756, SE = 1.875, p = 0.005), 
but not depression severity (B = 1.029, SE = 0.963, p = 0.294), 
were significant predictors for physical QoL. The EDSS correlated 
with PCS (ρ = −0.720, p < 0.001) but not with MCS (ρ = −0.223, 
p = 0.220).
Clinically relevant depression (B = −15.484, SE = 2.896, p < 0.001) 
was the only significant predictor for low mental QoL.
Symptomatic pain medication
Only 12 (54.5%) patients with MOGAD- related pain received pain 
medications. Treatment comprised nonsteroidal anti- inflammatory 
drugs and paracetamol (acetaminophen) (n = 10), anticonvulsants 
and/or antidepressants (n = 7), opioids (n = 2), and antispastic medi-
cation (n = 4). Five of 11 patients only retrospectively reported 
more than 50% reduction of pain intensity. Patients with nocicep-
tive pain received no (n = 6), one (n = 3), or two (n = 1) different 
pain medications. Six of 11 patients with definite or possible neuro-
pathic pain received three to six different types of pain medication. 
TA B L E  2  Demographics, clinical characteristics, BDI- II, and SF- 36 in patients with and without pain
Patients with MOGAD- related pain, 
n = 22
Patients without MOGAD- related 
pain, n = 21 p value
Sex, female/male (female %) 16/6 (72.7%) 13/8 (61.9%) 0.526
Age, years, mean ± SD 42.4 ± 12.8 35.9 ± 16.1 0.101
Age at disease onset, years, mean ± SD 37.6 ± 12.0 29.3 ± 15.0 0.039
Disease duration, years, median (min- max) 3 (0– 21) 3 (0– 43.7) 0.961
Total number of previous attacks, median (min- max)a 3.5 (1– 11) 3 (1– 16) 0.409
Patients with a history of myelitis, n (%)b 19 (86.4%) 15 (75.0%) 0.444
Patients with a history of ON, n (%)c 15 (75.0%) 15 (80.0%) >0.999
Total number of ON, median (min- max)d 2 (0– 5) 1 (0– 10) 0.881
Total number of myelitis, median (min- max)e 2 (0– 11) 1 (0– 4) 0.253
Self- reported visual function, median (min- max)f 1 (0– 4) 0 (0– 4) 0.557
Self- reported gait function, median (min- max)g 1 (0– 3) 0 (0– 1) 0.005
BDI- II, clinically relevant depression, n (%) 13 (59.1%) 5 (25.0%) 0.034
PCS, median (min- max)h 31.5 (9.4– 53.8) 51.0 (21.9– 65.8) <0.001
MCS, median (min- max)h 41.9 (27.3– 63.9) 50.0 (21.1– 63.3) 0.332
Note: These group comparisons were performed with the Fisher exact test for sex, BDI- II score categories, patients with ON/myelitis/both; and 
Wilcoxon test for age, disease duration, number of prior attacks, prior ON, and prior myelitis episodes, visual and gait function, PCS, and MCS (not 
normally distributed variables). Data available for an = 19 pain patients and n = 21 pain- free patients, bn = 22 pain patients and n = 20 pain- free 
patients, cn = 20 pain patients and n = 20 pain- free patients, dn = 19 pain patients and n = 19 pain- free patients, en = 20 pain patients and n = 17 pain- 
free patients, fn = 21 pain patients and n = 17 pain- free patients, gn = 18 pain patients and n = 21 pain- free patients, hn = 20 pain patients and n = 21 
pain- free patients. All bold p- values are significant (<0.05).
Abbreviations: BDI- II, Beck Depression Inventory II (clinically relevant depression was defined by scores ≥140); MCS, mental component summary 
(SF- 36); min- max, minimum– maximum; MOGAD, myelin oligodendrocyte glycoprotein- antibody– associated disease; n, number; ON, optic neuritis; 
PCS, physical component summary; SD, standard deviation; SF- 36, Short Form 36 Health Survey.
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The PSI correlated with the number of analgesic drugs (ρ = 0.536; 
p = 0.012).
Four of 15 patients with SAP received an antispastic medication. 
All of them still reported spasticity- associated pain attacks four, 10, 
12, and 60 times a month.
DISCUSSION
The present study highlights the importance of pain and depression 
in MOGAD. Over 40% of patients from this German multicenter 
cohort suffered from depression, and over 50% had nociceptive or 
neuropathic pain. Both comorbidities severely affected the patients’ 
QoL and were often untreated or resistant to treatment.
Recently, MOGAD has been acknowledged as a disease entity 
on its own, distinct from multiple sclerosis (MS) and NMOSD [5,7,8]. 
Underlying pathogenetic mechanisms, clinical presentation, attack 
severity, and remission rate are partly different in these diseases 
[5,7]. Differences on pain characteristics have also been supposed; 
however, specific data on pain in MOGAD are scarce [4,12,16,24,25]. 
Previous research mentioned pain mainly as part of acute symptoms 
in MOGAD attacks and focused on ON- related pain and neuropathic 
pain during relapses [2,4,14,24– 27]. In our cohort, 18 patients (42%) 
mentioned painful symptoms as part of their previous attacks. Most 
TA B L E  3  Comparison of measures of SF- BPI, MPQ- SF, BDI- II, and SF- 36 between patients with and without neuropathic pain
Patients with definite neuropathic 
pain, n = 8
Patients with definite nociceptive 
pain, n = 11 p value
Age, years, mean±SD 46.4 ± 9.0 41.3 ± 15.4 0.321
Sex, female/male (female %) 5/3 (62.5%) 9/2 (81.8%) 0.603
Disease duration, years, median (min- max) 3 (0– 13) 3 (0– 21) 0.921
Total number of previous attacks, median 
(min- max)a
3 (2– 8) 4 (1– 11) 0.725
Total number of ON, median (min- max)a 0.5 (0– 4) 1.5 (0– 5) 0.258
Total number of myelitis, median (min- max)b 2 (1– 8) 1 (0– 11) 0.352





Self- reported gait function, median (min- max)d 2 (0– 3) 0.5 (0– 1) 0.032
Present pain intensity, median (min- max) 6 (3– 9) 2 (0– 5) 0.002
Minimal pain intensity 3 (2– 9) 1 (0– 4) 0.003
Maximal pain intensity 8 (5– 9) 5 (1– 9) 0.027
Average pain intensity 5 (3– 9) 2 (1– 6) 0.010
Pain severity index 5.1 (3.8– 9) 2.8 (1– 4.8) 0.003
Activity of daily living
General activity 7 (5– 10) 4 (2– 8) 0.020
Mood 6.5 (3– 10) 4 (2– 8) 0.143
Walking ability 8.5 (3– 10) 3 (0– 10) 0.020
Working ability 9 (5– 10) 3 (2– 10) 0.008
Relations with other people 5.5 (2– 10) 2 (0– 9) 0.020
Sleep 6 (0– 9) 3 (0– 8) 0.183
Enjoyment of life 5 (0– 8) 2 (0– 7) 0.080
MPQ- SF, sensory category, median (min- max) 16.5 (6– 25) 5.5 (0– 12) 0.002
MPQ- SF, affective category, median (min- max) 5.0 (3– 12) 2.0 (0– 4) 0.004
BDI- II, clinically relevant depression, n (%) 6 (75.0%) 5 (45.5%) 0.352
PCS, median (min- max)c 20.5 (14.2– 34.8) 40 (9.4– 48.9) 0.016
MCS, median (min- max)c 36.5 (27.3– 53.5) 44.5 (31.2– 63.9) 0.122
Note: These group comparisons were performed using the Fisher exact test for sex and Wilcoxon test for all other (not normally distributed) variables. 
Data available for an = 8 patients with neuropathic pain and n = 8 patients with nociceptive pain, bn = 6 patients with neuropathic pain and n = 9 
patients with nociceptive pain, cn = 8 patients with neuropathic pain and n = 10 patients with nociceptive pain, dn = 7 patients with neuropathic pain 
and n = 8 patients with nociceptive pain. All bold p- values are significant (<0.05).
Abbreviations: BDI- II, Beck Depression Inventory II (clinically relevant depression was defined by scores ≥14); MCS, mental component summary 
(SF- 36); min- max, minimum– maximum; MPQ- SF, McGill Pain Questionnaire Short Form; n, number; ON, optic neuritis; PCS, physical component 
summary; SD, standard deviation; SF- 36, Short Form 36 Health Survey; SF- BPI, Short Form- Brief Pain Inventory.
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importantly, even more patients (51%) suffer from chronic MOGAD- 
related pain. Consequently, pain prevalence in MOGAD is similar to 
those in MS (estimated as 50%) and lower than in NMOSD, where 
pain prevalence has been reported to be as high as 80% to 86% [10– 
12,28]. However, estimates can differ in small studies, most likely 
due to heterogeneities of patient cohorts, screening instruments, 
and diverging pain classifications.
The prevalence of neuropathic pain in MOGAD probably ex-
ceeds that in MS [12,29]. About 26% of our patients suffered from 
neuropathic pain. In patients with MS, a prevalence of 29% has 
been reported in a meta- analysis, but a lower prevalence of 15% 
was found when more specific diagnostic criteria were used [30]. 
A recent study using the PDQ reported a prevalence of only 5% 
(compared to 18% in our cohort) of definite neuropathic pain in MS 
after a disease duration of 4 years [30]. In our cohort, patients with 
neuropathic pain were particularly disabled. Although average pain 
intensity in the whole cohort was mild, patients with neuropathic 
pain suffered from more severe pains, similar to those reported in 
TA B L E  5  Comparison of demographics and clinical characteristics between patients with and without clinically relevant depression
Patients with depression, 
n = 18
Patients without depression, 
n = 24 p value
Age, years, mean±SD 38.4 ± 12.7 38.0 ± 14.1 0.980
Sex, female/male (female %) 12/6 (66.7%) 16/8 (66.7%) >0.999
Disease duration, years, median (min- max) 2.5 (0– 9) 3.5 (0– 43.7) 0.160
Total number of previous attacks, median (min- max)a 4 (1– 11) 2.5 (1– 16) 0.334
Total nnumber of ON, median (min- max)b 1 (0– 10) 1 (0– 10) 0.880
Total number of myelitis, median (min- max)c 2 (0– 11) 1 (0– 10) 0.410
Self- reported visual function, median (min- max)d 1.0 (0– 4) 0.0 (0– 3) 0.078
Self- reported gait function, median (min- max)e 1.0 (0– 2) 0.0 n 0.001
Pain, n (%) 13 (72.2%) 9 (37.5%) 0.040
PCS, median (min- max)f 37.2 (9.4– 51.0) 48.0 (14.2– 65.8) 0.020
MCS, median (min- max)f 36.5 (25.7– 49.7) 50.1 (21.1– 63.9) <0.001
Note: These group comparisons were performed using the Fisher exact test for sex and Wilcoxon test for all other (not normally distributed) 
variables. Clinically relevant depression was defined by scores ≥14. Data available for an = 17 patients with and n = 22 patients without depression, 
bn = 17 patients with and n = 20 patients without depression, cn = 17 patients with and n = 19 patients without depression, dn = 17 patients with and 
n = 22 patients without depression, en = 12 patients with and n = 15 patients without depression, fn = 16 patients with and n = 24 patients without 
depression. All bold p- values are significant (<0.05).
Abbreviations: MCS, mental component summary (SF- 36); min- max, minimum– maximum; n, number; ON, optic neuritis; PCS, physical component 
summary; SD, standard deviation; SF- 36, Short Form 36 Health Survey.
TA B L E  4  Comparison of demographics and clinical characteristics between patients with and without spasticity- associated pain
Patients with spasticity- associated 
pain, n = 15
Patients without spasticity- 
associated pain, n = 7 p value
Age, years, mean±SD 41.2 ± 13.3 44.9 ± 12.3 0.548
Sex, female/male (female %) 12/3 (80.0%) 4/3 (75.0%) 0.330
Disease duration, years, median (min- max) 2.6 (0– 13) 5 (2– 21) 0.048
Total number of previous attacks, median 
(min- max)a
4 (2– 11) 2.3 (1– 5) 0.087
Patients with history of myelitis, n (%) 14 (93.3%) 5 (71.4%) 0.227
Total number of myelitis, median (min- max)b 2 (0– 11) 1 (0– 10) 0.142
Self- reported gait function, median (min- max)c 1.0 (0– 2) 1.0 (0– 3) 0.881
BDI- II, clinically relevant depression, n (%) 10 (66.7%) 3 (42.9%) 0.376
PCS, median (min- max)d 23.2 (9.4– 53.8) 41.9 (14.2– 48.9) 0.091
MCS, median (min- max)d 41.4 (27.3– 63.9) 42.5 (39.8– 53.5) 0.547
Note: These group comparisons were performed using the Fisher exact test for sex and BDI- II, and Wilcoxon test for all other (not normally 
distributed) variables. Data available for an = 13 patients with and n = 6 patients without SAP, bn = 13 patients with and n = 7 patients without SAP, 
cn = 12 patients with and n = 6 patients without SAP, dn = 14 patients with and n = 6 patients without SAP. All bold p- values are significant (<0.05).
Abbreviations: BDI- II, Beck Depression Inventory II (clinically relevant depression was defined by scores ≥14); MCS, mental component summary  
(SF- 36); min- max, minimum– maximum; n, number; PCS, physical component summary; SD, standard deviation; SF- 36, Short Form 36 Health Survey.
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NMOSD [12,29]. Neuropathic pain was significantly stronger and af-
fected the patients’ general activity, walking, and working capacities 
as well as relations to other people, compared to nociceptive pain.
Thirty- five percent of our MOGAD cohort suffered from SAP, 
and PTS occurred in about 9% of the patients. These numbers are 
lower than in NMOSD, where PTS occurs with a prevalence of 25% 
to 40% [13,31– 33].
Both neuropathic pain and SAP are most likely a consequence of a 
spinal cord damage. Although spinal cord lesions in NMOSD are typ-
ically long and extensive [34,35], spinal cord lesions in MOGAD can 
be smaller and less destructive. Still, due to the highly prevalent cen-
tral lesions location, they may frequently involve relevant structures 
of the pro- and antinociceptive system, resulting in chronic therapy- 
refractory pain and/or dysesthesia [4]. As reported for patients with 
AQP4- IgG positive NMOSD [36], the number of previous myelitis at-
tacks did not differ between patients with and without pain. Probably 
not a number of relapses, but precise axial lesion location, extension, 
and extent of tissue damage are decisive for chronic neuropathic and 
spasticity- associated pain. It has been shown that central neuropathic 
pain can be induced by oligodendrocyte death and axonal pathology 
in the spinothalamic tract [37]. Moreover, brainstem lesions can also 
facilitate the development of neuropathic pain by affection of ascend-
ing somatosensory fibers or descending inhibitory pathways [38,39].
A lower overall prevalence of pain in MOGAD may be linked to a 
better recovery of lesions compared to NMOSD [35]. We show that pa-
tients who were older at disease onset had a higher prevalence of pain, 
probably due to an age- dependent decrease of neuronal plasticity.
In addition to pain, depression was a relevant factor affecting 
the patients’ well- being. Similar to NMOSD [12,40], clinically rele-
vant depression occurred in 42% of the whole cohort and was sig-
nificantly more prevalent in pain sufferers (60%). Vice versa, pain 
was more prevalent in patients with depression. Both conditions are 
known to intensify each other and can worsen independently from 
relapses enhanced by central mechanisms [41].
Although pain severity was one of the strongest predictors of low 
physical QoL, clinically relevant depression predicted reduced mental 
QoL. Our data support the need for adequate prevention and prompt 
treatment of severe MOGAD relapses [5,9], as physical impair-
ment was directly associated with both depression and persistent— 
especially refractory neuropathic— pain. Of note, the relapse activity 
seems to also be associated with spasticity- associated pain.
We show the need of a systematic pain assessment in MOGAD, 
particularly as commonly used clinical assessment tools such as the 
EDSS do not cover pain. Moreover, our data indicate that pain is often 
undertreated or treated inadequately. In our cohort, patients with sev-
eral pain medications still had higher pain intensity scores, highlighting 
the importance of a targeted specific and/or multimodal pain therapy.
Limitations
The main limitation of our study is that information was based on 
a self- administered questionnaire without availability of clinical 
interview and neurological examination. Therefore, we cannot pro-
vide a definite diagnosis of specific pain syndromes, and our results 
do not allow for pathophysiological conclusions. We also had no spe-
cific data on possible medication- associated pain syndromes (e.g., 
due to steroid- induced osteonecrosis). However, only three patients 
received steroids at the time of assessment, and none of them in-
dicated having joint pain, corresponding to femoral head necrosis.
Only history of ON and myelitis were recorded, but no other pos-
sible syndromes (e.g., brainstem, cerebral). Therefore, our data on 
the respective type of previous attacks are incomplete. Moreover, 
we are aware that the questionnaire might be prone to selection 
bias, with patients suffering from pain having higher response rates. 
However, in three centers addressing 74% of the cohort, the re-
sponse rate was over 75%. Last, our study remains explorative, as 
we could not perform an a priori sample size calculation and adjust-
ments for multiple testing.
CONCLUSIONS
Overall, we show that chronic pain and depression are substantial is-
sues in MOGAD. Both conditions strongly reduce QoL and ADL, and 
are insufficiently controlled in clinical practice. Higher awareness 
of severely disabling neuropathic pain is of particular importance. 
Future research is needed to investigate precise underlying mecha-
nisms and elaborate specific pain treatment strategies.
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Achim Berthele, MD Technical University, Munich, 
Germany
achim.berthele@tum.de Organizational support
Felix Bischof, MD University Hospital, Tübingen, 
Germany
felix.bischof@uni-tuebingen.de Organizational support
Stefan Bittner, MD University Medical Center of the 
Johannes Gutenberg University, 
Mainz, Germany
stefan.bittner@unimedizin-mainz.de Organizational support
Tobias Böttcher, MD Johanna- Odebrecht- Stiftung, 
Greifswald, Germany
toboettcher@gmx.de Organizational support
Mathias Buttmann, MD University of Würzburg, Germany mathias.buttmann@ckbm.de Organizational support





Barbara Ettrich, MD University Hospital, Leipzig, Germany barbara.ettrich@medizin.uni-leipzig.
de
Organizational support
Jürgen Faiss, MD Asklepios Klinik, Teupitz, Germany j.faiss@asklepios.com Organizational support
Benedikt Frank, MD University Hospital, Essen, Germany benedikt.frank@uk-essen.de Organizational support





Christian Geis Department of Neurology, Jena 
University Hospital, Germany
christian.geis@med.uni-jena.de Organizational support
Matthias Grothe, MD University Hospital, Greifswald, 
Germany
matthias.grothe@uni-greifswald.de Organizational support
Kerstin Guthke, MD Klinikum Görlitz, Germany guthke.kersten@klinikum-goerlitz.de Organizational support
Axel Haarmann, MD University of Würzburg, Germany haarmann_a@ukw.de Organizational support





Kerstin Hellwig, MD Ruhr University of Bochum, Germany k.hellwig@klinikum-bochum.de Organizational support
Bernhard Hemmer, MD Technical University, Munich, 
Germany
bernhard.hemmer@mri.tum.de Organizational support
Frank Hoffmann, MD Krankenhaus Martha- Maria, Halle, 
Germany
frank.hoffmann@martha-maria.de Organizational support
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Jutta Junghans, MD Krankenhaus Martha- Maria, Halle, 
Germany
jutta.junghans@martha-maria.de Organizational support
Matthias Kaste, MD Nordwest Hospital Sanderbusch, 
Sande, Germany
m.kaste@sanderbusch.de Organizational support
Barbara Kaulen, MD University Hospital, Hamburg, 
Germany
b.kaulen@uke.de Organizational support
Pawel Kermer, MD Nordwest Hospital Sanderbusch, 
Sande, Germany
p.kermer@sanderbusch.de Organizational support
Peter Kern, MD Asklepios Klinik, Teupitz, Germany pe.kern@asklepios.com Organizational support
Christoph Kleinschnitz, MD University Hospital, Essen, Germany christoph.kleinschnitz@uk-essen.de Organizational support
Wolfgang Köhler, MD University Hospital, Leipzig, Germany wolfgang.koehler@medizin.uni-
leipzig.de
Organizational support




















Stefan Langel, MD Landeskrankenhaus Rheinhessen, 
Germany
s.langel@rfk.landeskrankenhaus.de Organizational support
De- Hyung Lee, MD University Hospital, Regensburg, 
Germany
de-hyung.lee@medbo.de Organizational support
Martin Liebetrau, MD St. Josefs- Hospital, Wiesbaden, 
Germany
mliebetrau@joho.de Organizational support
Ralf Linker, MD University Hospital, Regensburg, 
Germany
ralf.linker@ukr.de Organizational support
Felix Luessi, MD University Medical Center of the 
Johannes Gutenberg University, 
Mainz, Germany
luessi@uni-mainz.de Organizational support
Martin Marziniak, MD Isar- Amper Klinik Ost, Munich, 
Germany
martin.marziniak@kbo.de Organizational support
Christoph Mayer, MD Neurologischen Gemeinschaftspraxis 
im Bienenkorbhaus, Frankfurt, 
Germany
praxis@neurologie-ffm.de Organizational support
Stefanie Meister, MD University Hospital, Rostock, Germany stefanie.meister@med.uni-rostock.
de
Organizational support
Arthur Melms, MD Facharztpraxis für Neurologie und 
Psychiatrie, Stuttgart, Germany
praxis@neurologen-stuttgart.de Organizational support
Imke Metz, MD University Hospital, Göttingen, 
Germany
imetz@gwdg.de Organizational support
Oliver Neuhaus, MD SRH Krankenhaus, Sigmaringen, 
Germany
oliver.neuhaus@srh.de Organizational support
Sabine Niehaus, MD Klinikum Dortmund, Germany sabine.niehaus@klinikumdo.de Organizational support
Florence Pache, MD Charité University Medicine, Berlin, 
Germany
florence.pache@charite.de Organizational support
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Refik Pul, MD University Hospital, Essen, Germany refik.pul@uk-essen.de Organizational support
Paulus Rommer, MD Medical University of Wien, Austria paulus.rommer@meduniwien.ac.at Organizational support
Kevin Rostásy, MD Vestische Caritas- Kliniken GmbH, 
Datteln, Germany
k.rostasy@kinderklinik-datteln.de Organizational support
Lioba Rückriem, MD MediClin Hedon- Klinik, Lingen (Ems), 
Germany
lioba.rueckriem@mediclin.de Organizational support
Klemens Ruprecht, MD Charité University Medicine, Berlin, 
Germany
klemens.ruprecht@charite.de Organizational support





Sven Schippling, MD University Hospital, Zürich, 
Switzerland
sven.schippling@usz.ch Organizational support
Matthias Schwab, MD University Hospital, Jena, Germany matthias.schwab@med.uni-jena.de Organizational support
Makbule Senel, MD University Hospital, Ulm, Germany makbule.senel@uni-ulm.de Organizational support
Jörn Peter Sieb, MD Helios Hanseklinikum, Stralsund, 
Germany
joern-peter.sieb@helios-kliniken.de Organizational support
Claudia Sommer, MD University Hospital, Würzburg, 
Germany
sommer@uni-wuerzburg.de Organizational support
Annette Spreer, MD University Medical Center of the 





Martin Stangel, MD Hannover Medical School, Hannover, 
Germany
stangel.martin@mh-hannover.de Organizational support
Andrea Steinbrecher, MD Helios Klinikum, Erfurt, Germany andreas.steinbrecher@helios-
kliniken.de
Organizational support
Jan- Patrick Stellmann, MD University Hospital, Hamburg, 
Germany
jan-patrick.stellmann@univ-amu.fr Organizational support
Heike Stephanik, MD University Hospital, Magdeburg, 
Germany
heike.stephanik@med.ovgu.de Organizational support
Muriel Stoppe, MD University Hospital, Leipzig, Germany muriel.stoppe@medizin.uni-leipzig.
de
Organizational support
Marie Süße, MD University Hospital, Greifswald, 
Germany
suessem@uni-greifswald.de Organizational support
Björn Tackenberg, MD University Hospital, Marburg, 
Germany
tackenbb@staff.uni-marburg.de Organizational support
Florian Then- Bergh, MD University Hospital, Leipzig, Germany florian.thenbergh@medizin.uni-
leipzig.de
Organizational support
Hayrrettin Tumani, MD University Hospital, Ulm, Germany hayrettin.tumani@rku.de Organizational support





Annette Walter, MD Klinikum Herford, Herford, Germany annette.walter@klinikum-herford.de Organizational support
Klaus- Peter Wandinger, MD University Medical Center Schleswig- 
Holstein Campus, Lübeck, 
Germany
klaus-peter.wandinger@uksh.de Organizational support
Clemens Warnke, MD University Hospital, Köln, Germany clemens.warnke@uk-koeln.de Organizational support





Robert Weissert, MD University Hospital, Regensburg, 
Germany
robert.weissert@ukr.de Organizational support
Heinz Wiendl, MD University Hospital, Münster, 
Germany
heinz.wiendl@ukmuenster.de Organizational support
Christian Wilke, MD Nervenzentrum, Potsdam, Germany Organizational support
(Continues)
APPENDIX 1 (Continued)
1658  |    ASSEYER Et Al.
Name Location Email Contribution
Alexander Winkelmann, MD University Hospital, Rostock, Germany alexander.winkelmann@med.uni-
rostock.de
Organizational support
Yavor Yalachkov, MD University Hospital, Frankfurt, 
Germany
yavor.yalachkov@kgu.de Organizational support
Lena Zeltner, MD University Hospital, Tübingen, 
Germany
lena.zeltner@uni-tuebingen.de Organizational support
Uwe Zettl University Hospital, Rostock, Germany uwe.zettl@med.uni-rostock.de Organizational support
Ulf Ziemann, MD University Hospital, Tübingen, 
Germany
ulf.ziemann@med.uni-tuebingen.de Organizational support
Frauke Zipp, MD University Medical Center of the 
Johannes Gutenberg University, 
Mainz, Germany
frauke.zipp@unimedizin-mainz.de Organizational support
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